A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Last updated: January 9, 2024
Sponsor: Bristol-Myers Squibb
Overall Status: Active - Recruiting

Phase

N/A

Condition

Multiple Sclerosis

Memory Loss

Scar Tissue

Treatment

N/A

Clinical Study ID

NCT05658601
IM047-1038
  • Ages 18-55
  • All Genders

Study Summary

The purpose of this study is to describe the reasons, therapy, and/or disease for changing first or second line Disease Modifying Therapy (DMT) to ozanimod in participants with Relapsing Remitting Multiple Sclerosis (RRMS).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with RRMS according to 2017 revised McDonald criteria
  • Patients who switched a previous first or second line DMT to ozanimod between 4 and 12weeks before the enrollment
  • Patient with a MRI performed within three months before the enrollment
  • Patient eligible to ozanimod according to SmPC

Exclusion

Exclusion Criteria:

  • Patients with clinical forms of MS other than RRMS
  • Patients unable to participate for various reasons
  • Patients participating in another clinical study with an investigational product ifthe study considers the switching behavior as an endpoint or objective
  • Contraindications to ozanimod according to SmPC Other protocol-defined Inclusion/Exclusion Criteria apply.

Study Design

Total Participants: 180
Study Start date:
July 14, 2023
Estimated Completion Date:
January 31, 2027

Connect with a study center

  • Neuromed Istituto Neurologico Mediterraneo

    Isernia, 86077
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.